Olmesartan attenuates doxorubicin-elicited testicular toxicity: The interaction between sirtuin-1, HMGB1/NLRP3 inflammasome/gasdermin D signaling, and AMPK/mTOR-driven autophagy
Life Sciences · 2025
DOI: 10.1016/j.lfs.2025.123545 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Sciences, 2025. Verfasst von Hemat A Elariny und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, College of Pharmacy, University of Ha'il, Ha'il 81442, Saudi Arabia. Hauptthemen laut MEDLINE: Imidazoles, Doxorubicin, Testis, Tetrazoles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 114 Literaturangaben. Gefördert von: University of Hail.
Abstract (Originalsprache)
BACKGROUND: In the recent years, there has been an increased incidence of testicular toxicity associated with doxorubicin (DOX) use in cancer therapy. The mechanisms of this adverse effect may include induction of oxidative stress with augmentation of the inflammatory and the apoptotic signals in the testicular tissues. The ongoing research is directed towards the exploration of new agents that are capable of overcoming this health problem. This study was a trial to evaluate the efficacy of Olmesartan as a protective agent against DOX-induced testicular dysfunction in male rats. MATERIALS AND METHODS: Forty adult male Sprague-Dawley rats were divided into control group, DOX-injected group, and three DOX-injected groups treated with olmesartan at 3 dose levels (1, 5, and 10 mg/kg/day). The effect of the different treatments was assessed at the biochemical and the morphological levels. KEY FINDINGS: Olmesartan administered to DOX-treated rats induced dose-dependent restoration of the testicular weight and functions, normalization of the hormonal profile, augmentation of the antioxidant defenses, and potentiation of AMPK/mTOR-driven autophagy in comparison to rats treated with DOX alone. These effects were accompanied with a dose-dependent significant mitigation of the cellular events related to pyroptosis and inflammation and a significant amelioration of the testicular morphological changes induced by DOX. SIGNIFICANCE: Olmesartan may represent a promising therapy for DOX-elicited testicular dysfunction, possibly via dose-dependent antioxidant, anti-pyroptotic, anti-inflammatory, and autophagy enhancing effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, College of Pharmacy, University of Ha'il, Ha'il 81442, Saudi Arabia.
- Department of Pharmaceutics, College of Pharmacy, University of Ha'il, Ha'il 81442, Saudi Arabia.
- Department of Pathology, College of Medicine, University of Ha'il, Ha'il 81442, Saudi Arabia.
- Pharmacology Department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt.
- Pharmacology Department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt. Electronic address: ahmed.kabal@med.tanta.edu.eg.
Förderung
- University of Hail
Zitieren
APA
Elariny, H. A., Atia, H. A., Abdallah, M. H., Khalifa, A. M., Abd Elmaaboud, M. A., Elkady, M. A., & Kabel, A. M. (2025). Olmesartan attenuates doxorubicin-elicited testicular toxicity: The interaction between sirtuin-1, HMGB1/NLRP3 inflammasome/gasdermin D signaling, and AMPK/mTOR-driven autophagy. Life Sciences. https://doi.org/10.1016/j.lfs.2025.123545
Vancouver
Elariny HA, Atia HA, Abdallah MH, Khalifa AM, Abd Elmaaboud MA, Elkady MA, et al. Olmesartan attenuates doxorubicin-elicited testicular toxicity: The interaction between sirtuin-1, HMGB1/NLRP3 inflammasome/gasdermin D signaling, and AMPK/mTOR-driven autophagy. Life Sciences. 2025. doi:10.1016/j.lfs.2025.123545
BibTeX
@article{Elariny2025,
author = {Elariny, Hemat A and Atia, Hanan Abdelmawgoud and Abdallah, Marwa H and Khalifa, Amany M and Abd Elmaaboud, Maaly A and Elkady, Mennatallah A and Kabel, Ahmed M},
title = {Olmesartan attenuates doxorubicin-elicited testicular toxicity: The interaction between sirtuin-1, HMGB1/NLRP3 inflammasome/gasdermin D signaling, and AMPK/mTOR-driven autophagy},
journal = {Life Sciences},
year = {2025},
doi = {10.1016/j.lfs.2025.123545}
}
EUVIMED